Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 6.70
Day High 6.85
Open:6.84
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports+

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Notice of Knight Therapeutics' Second Quarter 2020 Results Conference Call
- GlobeNewswire - Thu Aug 6, 6:30AM CDT
GlobeNewswire - CMTX
Thu Aug 6, 6:30AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2020 financial results on Thursday, August 13, 2020 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.
Knight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo Biotoscana
- GlobeNewswire - Wed Jul 15, 6:30AM CDT
GlobeNewswire - CMTX
Wed Jul 15, 6:30AM CDT
Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight") today announced the launch of the tender offer and the release of the notice for the tender offer process filed by 1178991 CANADA INC. for the acquisition and delisting of all outstanding Brazilian Depositary Receipts of Biotoscana Investments S.A.
Knight Announces Normal Course Issuer Bid
- GlobeNewswire - Fri Jul 10, 6:30AM CDT
GlobeNewswire - CMTX
Fri Jul 10, 6:30AM CDT
Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 10,856,710 common shares of the Company, being approximately 10% of its public float of 108,567,101 common shares, as of July 6, 2020. As of July 6, 2020, there were a total of 130,938,418 common shares issued and outstanding. Purchases may commence on July 14, 2020 and will conclude on the earlier of the date on which purchases under the bid have been completed and July 13, 2021. The Company may purchase up to a daily maximum of 86,321 Shares (being 25% of the average daily trading volume of 345,284 shares, for the last six calendar months). The common shares may be purchased for cancellation through the facilities of the TSX or through alternative Canadian trading systems at times and in numbers to be determined by the Company. The Company had previously sought and obtained approval from the TSX to purchase up to 12,053,693 common shares under an NCIB and the Company has, in the twelve months preceding this announcement, purchased such 12,053,692 common shares through the facilities of the TSX and alternative Canadian trading systems at a weighted average price per share of $7.14.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 6.61 +2.87% increase
on 07/24/20
Period Open:7.06
Price movement based on the high, low and last over the given period.
7.13 -4.63% decrease
on 07/13/20
-0.26 (-3.68%) decrease
since 07/06/20
3-Month 6.51 +4.45% increase
on 06/26/20
Period Open:7.81
Price movement based on the high, low and last over the given period.
7.84 -13.27% decrease
on 05/08/20
-1.01 (-12.93%) decrease
since 05/06/20
52-Week 4.73 +43.76% increase
on 03/19/20
Period Open:7.45
Price movement based on the high, low and last over the given period.
8.88 -23.42% decrease
on 10/23/19
-0.65 (-8.72%) decrease
since 08/06/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies